Apnex, Inc., is a biotechnology firm that is about to announce the results of its clinical trials of a potential new cancer drug. If the trials are successful, Apnex stock will be worth $67 per share. If the trials are unsuccessful, Apnex stock will be worth $17 per share. Suppose that the morning before the announcement is scheduled, Apnex shares are trading for $56 per share. a. Based on the current share price, what sort of expectations do investors seem to have about the success of the trials? b. Suppose hedge fund manager Paul Kliner has hired several prominent research scientists to examine the public data on the drug and make their own assessment of the drug's promise. Would Kliner's fund be likely to profit by trading the stock in the hours prior to the announcement? C. Which factors would limit the ability of Kliner's fund to profit on its information? a. Based on the current share price, what sort of expectations do investors seem to have about the success of the trials? (Select the best choice below.) A. The market seems to believe the trials will not be successful. OB. The market seems to assess a somewhat greater than 50% chance of success. C. The market seems to have no clue about what will happen to the stock price. OD. The market seems to expect a 50% decline in the stock price